GlycoMimetics Inc reports results for the quarter ended in March - Earnings Summary

Crescent Biopharma

28/04/2022 14:31

* GlycoMimetics Inc  GLYC.OQ  reported a quarterly adjusted
loss
of 28 cents​​ per share for the quarter ended in March. The mean
expectation of four analysts for the quarter was for a loss
of 31 cents per share.
    * Reported revenue was zero​;  analysts expected zero. 
    * The mean earnings estimate of analysts had risen by
about 8% in
the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * GlycoMimetics Inc shares had fallen by 26.3% this
quarter and
lost 41.7% so far this year.
    * The company reported a quarterly loss of $14.65 million.
    * Wall Street's median 12-month price target for
GlycoMimetics Inc
is $14.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated April 28 at 01:31 p.m.  ​All
figures in US dollars unless otherwise stated